# SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Source: https://onco.cc/trials/nct06394492/  
OnCo record `nct06394492` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing SHR-A1921 in ovarian cancer, now recruiting.

## Summary

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer is a phase 3 interventional study registered as NCT06394492, led by Suzhou Suncadia Biopharmaceuticals, and recruiting on the registry. Official title: A Randomised, Open-Label, Controlled, Phase III Study of SHR-A1921 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer. Planned enrolment is 440 participants (estimated). The study started in 2024-05-10 and primary completion is expected in 2026-05-31. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06394492
- Phase: 3
- Setting: A Randomized, Open-Label, Controlled, Phase III Study of SHR-A1921 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
- Sponsor: Suzhou Suncadia Biopharmaceuticals
- Enrolled: 440

## Sources

- ClinicalTrials.gov NCT06394492: https://clinicaltrials.gov/study/NCT06394492

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- drugs: [SHR-A1921](https://onco.cc/drugs/shr-a1921/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06394492.json